Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

BACKGROUND: PROSTVAC®, an active immunotherapy currently studied for the treatment of metastatic castration-resistant prostate cancer (mCRPC), consists of a heterologous prime-boost regimen with two different poxvirus-based vectors to provoke productive immune responses against prostate specific ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandl, Stefanie J, Rountree, Ryan B, dela Cruz, Tracy B, Foy, Susan P, Cote, Joseph J, Gordon, Evan J, Trent, Erica, Delcayre, Alain, Franzusoff, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201731/
https://www.ncbi.nlm.nih.gov/pubmed/25328681
http://dx.doi.org/10.1186/s40425-014-0034-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201731/
https://www.ncbi.nlm.nih.gov/pubmed/25328681
http://dx.doi.org/10.1186/s40425-014-0034-0

Ejemplares similares